Thomas Knittel
Direttore Tecnico/Scientifico/R&S presso InDex Pharmaceuticals AB
Posizioni attive di Thomas Knittel
Società | Posizione | Inizio | Fine |
---|---|---|---|
InDex Pharmaceuticals AB
InDex Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology InDex Pharmaceuticals AB is a pharmaceutical development company, which engages in the research, development of technology, and commercialization of scientific discoveries focusing on immunological diseases. It also offers the drug candidate cobitolimod and DiBiCol diagnostic kit. The company was founded was founded on December 14, 2015 and is headquartered in Solna, Sweden. | Direttore Tecnico/Scientifico/R&S | 01/01/2012 | - |
HepaRegeniX GmbH
HepaRegeniX GmbH Miscellaneous Commercial ServicesCommercial Services HepaRegeniX GmbH engages in the development of treatment for acute and chronic liver diseases. It focuses on Mitogen-Activated Protein Kinase 4, which unlocks the regenerative capacity of hepatocytes even in severely diseased livers. The company was founded in by Wolfgang Albrecht in 2017 and is headquartered in Tuebingen, Germany. | Direttore/Membro del Consiglio | - | - |
Independent Dir/Board Member | - | - |
Storia della carriera di Thomas Knittel
Precedenti posizioni note di Thomas Knittel
Società | Posizione | Inizio | Fine |
---|---|---|---|
FLERIE INVEST AB | Direttore Tecnico/Scientifico/R&S | 01/01/2012 | 02/05/2022 |
Harlan Laboratories, Inc.
Harlan Laboratories, Inc. Miscellaneous Commercial ServicesCommercial Services Harlan Laboratories, Inc. provided essential, pre-clinical and non-clinical contract research, research models, lab animal diets and services. The firm's focused on providing customers with products and services to optimize the discovery and safety of new medicines and compounds. The company was founded in 1931 and was headquartered in Indianapolis, IN. | Corporate Officer/Principal | - | 01/01/2011 |
NOVO NORDISK A/S | Vendite & Marketing | - | 01/01/2010 |
Novo Nordisk Pharma GmbH
Novo Nordisk Pharma GmbH Pharmaceuticals: MajorHealth Technology Novo Nordisk Pharma GmbH manufacturers and distributes pharmaceutical products. It offers pharmaceutical products for diabetes, menopause, growth hormones and blood clotting which treats chronic diseases: hemophilia, growth disorders and obesity. The company was founded in 1991 and is headquartered in Mainz, Germany. | Vendite & Marketing | - | 01/01/2010 |
University of Gottingen | Corporate Officer/Principal | - | - |
DeveloGen AG
DeveloGen AG Pharmaceuticals: MajorHealth Technology DeveloGen AG is a biopharmaceutical company engaged in the discovery and development of novel therapeutics for the treatment of metabolic and endocrine disorders with a particular focus on diabetes. DeveloGen develops highly innovative approaches for the treatment of diabetes and obesity targeting key pathophysiological mechanisms such as insulin resistance and loss of insulin-producing beta cells. DeveloGen's product pipeline includes two programs at advanced stages of lead optimization, a small molecule inhibitor program based on a novel and proprietary target to address insulin resistance (type 2 diabetes). A growth factor targeting beta cell regeneration (type 1 and type 2 diabetes). DeveloGen is based in Goettingen, Germany. | Corporate Officer/Principal | - | - |
Formazione di Thomas Knittel
Kellogg School of Management | Masters Business Admin |
University of Maine | Doctorate Degree |
Statistiche
Distribuzione geografica
Germania | 5 |
Stati Uniti | 4 |
Svezia | 3 |
Posizioni
Corporate Officer/Principal | 3 |
Chief Tech/Sci/R&D Officer | 2 |
Sales & Marketing | 2 |
Settori
Health Technology | 6 |
Consumer Services | 4 |
Commercial Services | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 2 |
---|---|
FLERIE INVEST AB | Health Technology |
NOVO NORDISK A/S | Health Technology |
Aziende private | 5 |
---|---|
Harlan Laboratories, Inc.
Harlan Laboratories, Inc. Miscellaneous Commercial ServicesCommercial Services Harlan Laboratories, Inc. provided essential, pre-clinical and non-clinical contract research, research models, lab animal diets and services. The firm's focused on providing customers with products and services to optimize the discovery and safety of new medicines and compounds. The company was founded in 1931 and was headquartered in Indianapolis, IN. | Commercial Services |
DeveloGen AG
DeveloGen AG Pharmaceuticals: MajorHealth Technology DeveloGen AG is a biopharmaceutical company engaged in the discovery and development of novel therapeutics for the treatment of metabolic and endocrine disorders with a particular focus on diabetes. DeveloGen develops highly innovative approaches for the treatment of diabetes and obesity targeting key pathophysiological mechanisms such as insulin resistance and loss of insulin-producing beta cells. DeveloGen's product pipeline includes two programs at advanced stages of lead optimization, a small molecule inhibitor program based on a novel and proprietary target to address insulin resistance (type 2 diabetes). A growth factor targeting beta cell regeneration (type 1 and type 2 diabetes). DeveloGen is based in Goettingen, Germany. | Health Technology |
InDex Pharmaceuticals AB
InDex Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology InDex Pharmaceuticals AB is a pharmaceutical development company, which engages in the research, development of technology, and commercialization of scientific discoveries focusing on immunological diseases. It also offers the drug candidate cobitolimod and DiBiCol diagnostic kit. The company was founded was founded on December 14, 2015 and is headquartered in Solna, Sweden. | Health Technology |
Novo Nordisk Pharma GmbH
Novo Nordisk Pharma GmbH Pharmaceuticals: MajorHealth Technology Novo Nordisk Pharma GmbH manufacturers and distributes pharmaceutical products. It offers pharmaceutical products for diabetes, menopause, growth hormones and blood clotting which treats chronic diseases: hemophilia, growth disorders and obesity. The company was founded in 1991 and is headquartered in Mainz, Germany. | Health Technology |
HepaRegeniX GmbH
HepaRegeniX GmbH Miscellaneous Commercial ServicesCommercial Services HepaRegeniX GmbH engages in the development of treatment for acute and chronic liver diseases. It focuses on Mitogen-Activated Protein Kinase 4, which unlocks the regenerative capacity of hepatocytes even in severely diseased livers. The company was founded in by Wolfgang Albrecht in 2017 and is headquartered in Tuebingen, Germany. | Commercial Services |
- Borsa valori
- Insiders
- Thomas Knittel
- Esperienza